Antengene Acquires Full Rights to Calithera’s CD73 Inhibitor CB-708
China-based Antengene Corporation Ltd (HKG: 6996) has unveiled a transfer agreement with US-headquartered Calithera Biosciences...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity